Mutational analysis of bone marrow mesenchymal stromal cells in myeloid malignancies

Experimental Hematology

Volumn 42, Issue 9, 2014, Pages 731-733

  Fabiani, Emiliano ^a   Falconi, Giulia ^a   Fianchi, Luana ^a   Guidi, Francesco ^a   Bellesi, Silvia ^a   Voso, Maria Teresa ^a   Leone, Giuseppe ^a   D'Alò, Francesco ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD135 ANTIGEN; DNA METHYLTRANSFERASE 3A; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; NUCLEOPHOSMIN; TUMOR PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; BONE MARROW DERIVED MONONUCLEAR CELL; CLINICAL ARTICLE; DNMT3A GENE; FLT3 GENE; GENE; GENE MUTATION; HEMATOLOGIC MALIGNANCY; HETEROZYGOSITY; HUMAN; HUMAN CELL; IDH1 GENE; IDH2 GENE; LETTER; MESENCHYMAL STROMA CELL; MUTATIONAL ANALYSIS; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE NEOPLASM; NPM1 GENE; PRIORITY JOURNAL; SF3B1 GENE; SRFS2 GENE; U2AF1 GENE; ARTICLE; FEMALE; GENETICS; HEMATOLOGIC DISEASE; MALE; MYELOPROLIFERATIVE DISORDER; NUCLEOTIDE SEQUENCE;

DNA MUTATIONAL ANALYSIS; FEMALE; HEMATOLOGIC NEOPLASMS; HUMANS; MALE; MESENCHYMAL STROMAL CELLS; MYELOPROLIFERATIVE DISORDERS; NEOPLASM PROTEINS;

EID: 84908504773     PISSN: 0301472X     EISSN: 18732399     Source Type: Journal    
DOI: 10.1016/j.exphem.2014.04.011     Document Type: Letter

References (10)

1. Dominici M., Le Blanc K., Mueller I., et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006, 8:315-317.
2. Geyh S., Oz S., Cadeddu R.P., et al. Insufficient stromal support in MDS results from molecular and functional deficits of mesenchymal stromal cells. Leukemia 2013, 27:1841-1851.
3. Blau O., Baldus C.D., Hofmann W.K., et al. Mesenchymal stromal cells of myelodysplastic syndrome and acute myeloid leukemia patients have distinct genetic abnormalities compared with leukemic blasts. Blood 2011, 118:5583-5592.
4. Ley T.J., Ding L., Walter M.J., et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med 2010, 363:2424-2433.
5. Mardis E.R., Ding L., Dooling D.J., et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 2009, 361:1058-1066.
6. Yoshida K., Sanada M., Shiraishi Y., et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 2011, 478:64-69.
7. Voso M.T., Fabiani E., Fianchi L., et al. Mutations of epigenetic regulators and of the spliceosome machinery in therapy-related myeloid neoplasms and in acute leukemias evolved from chronic myeloproliferative diseases. Leukemia 2013, 27:982-985.
8. Walter M.J., Ding L., Shen D., et al. Recurrent DNMT3A mutations in patients with myelodysplastic syndromes. Leukemia 2011, 25:1153-1158.
9. Patnaik M.M., Hanson C.A., Hodnefield J.M., et al. Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: A Mayo Clinic study of 277 patients. Leukemia 2012, 26:101-105.
10. Przychodzen B., Jerez A., Guinta K., et al. Patterns of missplicing due to somatic U2AF1 mutations in myeloid neoplasms. Blood 2013, 122:999-1006.